Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid‐independent mechanism
Samuel Chao Ming Yeo(National University of Singapore), Louise Donnelly(Lung Institute)
Cited by 74
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
|The Lancet Respiratory Medicine|2022|58
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
|medRxiv|2021|25
Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial
|SSRN Electronic Journal|2021|5